Pharma news
Pharma
The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines. 17 May 2021
Pharma
The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid. 13 May 2021
Pharma
Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents. 13 May 2021
Pharma
India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India. 13 May 2021
Pharma
MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent. 11 May 2021
Pharma
Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals. 6 May 2021
Americas
Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments. 4 May 2021
Americas
GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.” 29 April 2021
Pharma
Ghana’s pharmaceutical industry has asked AstraZeneca about acquiring rights to produce its COVID vaccine locally, buoying the country’s inoculation efforts. 27 April 2021
Pharma
Pfizer has discovered counterfeit versions of its COVID-19 vaccine in Mexico and Poland, prompting governments to reassure the public over the safety of vaccine supply chains. 27 April 2021